Mon, March 21, 2022
Sun, March 20, 2022
Fri, March 18, 2022
Thu, March 17, 2022
Wed, March 16, 2022
Tue, March 15, 2022
Mon, March 14, 2022
Fri, March 11, 2022
Thu, March 10, 2022

Tazeen Ahmad Upgraded (ASND) to Strong Buy and Increased Target to $161 on, Mar 15th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. nd-increased-target-to-161-on-mar-15th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Tazeen Ahmad of B of A Securities, Upgraded "Ascendis Pharma A/S" (ASND) to Strong Buy and Increased Target from $148 to $161 on, Mar 15th, 2022.

Tazeen has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 4 analyists that currently disagree with Tazeen


  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $194 on, Monday, March 14th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022

Publication Contributing Sources